Reverse cholesterol transport
Arteriosclerosis remains the number 1 cause of death in the United States and the developed world. Reverse cholesterol transport, the removal of cholesterol from arterial plaques, is one of the most sought after therapeutic targets by big pharma today. KineMed is unique in its ability to identify drugs that increase RCT in both animals and patients.

Insulin resistance
Untreated insulin resistance is associated with progression of diabetes and cardiovascular disease. In addition, insulin resistance is the underlying metabolic imbalance of pre-diabetes and the metabolic syndrome, which has become epidemic in the US. KineMed's minimally invasive method directly measures both insulin resistance and the level of pancreatic function in humans and animals.

Neurological diseases
As the Baby Boom generation enters the age of greatest risk, the incidence of neurodegenerative diseases is increasing rapidly. For example, the number of people with Alzheimer's disease, the primary cause of dementia in the elderly, is expected triple by 2050. The incidence of Parkinson's disease and amyotrophic lateral sclerosis is also increasing. KineMed accurately measures changes in the dynamics of microtubules and is developing drugs that treat these changes in axons before damage occurs.

Osteoarthritis, fibrosis, and inflammation
Osteoarthritis is by far the most common type of arthritis, and the percentage of people who have it grows higher with age. Nearly 21 million Americans, age 25 and older, have osteoarthritis. As our population ages, this number will only grow. By 2030, 20% of Americans—about 72 million people—will be over 65 years of age and at high risk for the disease. KineMed directly measures the ability of drugs to treat the underlying process of osteoarthritis and inflammation.

Others
KineMed research is actively engaged in applying its pathway -based translational medicine to discover how to modulate the kinetics of metabolic pathways that are the fundamental basis for important diseases.

KineMed's Unique Pathway -Based Approach

• KineMed's drug discovery and development programs apply proprietary technologies to measure the true effects of drugs-modulation of kinetics of disease pathways in live animals and patients.
• Pathway kinetics efficiently translates chemistry into biology and accurately predicts therapeutic efficacy.
• By measuring therapeutic effects in intact animals, KineMed's preclinical drug candidate screening and development is more predictive of human outcomes.
• Application of KineMed technologies to key pathways in multiple diseases creates a broad development and partner program pipeline.

KineMed's Translational Medicine Focus

• Many human pathways can be measured and represent powerful "targets" for drug development.
• Translational medicine is the science of developing more predictive transitions from preclinical animal efficacy to human efficacy.
• When possible, KineMed has developed the ability to perform the symmetrical pathway -based efficacy experiments in patients.
• In both partner collaborations and its internal development, KineMed "de-risks" clinical drug development by confirming that a drug candidate's efficacy and dose response in First-in-Man studies